Ligand Pharmaceuticals (LGND) executive compensation, 2026 proxy

Todd C. Davis, Chief Executive Officer, was paid $11.5M in 2025, down 11% from $12.9M the year before. The CEO-to-median-employee pay ratio was 28:1, on median employee pay of $403,453.

Filed
April 21, 2026
Annual meeting
June 5, 2026
Pay year
2025
Named executives
3
CEO total pay
$11.5M-11% vs prior year
CEO to median employee
28:1median $403,453
CEO pay in equity
87%$10M in awards
Prior say-on-pay support
93%of votes cast
CEO At-Risk Pay
94%Percentage of target direct compensation
Other NEO At-Risk Pay
87%Percentage of target direct compensation
Royalty Revenue Growth
48%Increase over 2024
Adjusted Net Income
$165.1MFull year 2025

How Davis was paid

$11.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary6%Stock awards48%Option awards39%Non-equity incentive7%All other compensation0%

Named executive officers

ExecutiveTotal
Todd C. DavisChief Executive Officer$11,472,095
Tavo EspinozaChief Financial Officer$4,382,148
Andrew ReardonChief Legal Officer and Secretary$3,747,282

What changed and why

  • 48%Royalty revenue increased by approximately 48% over 2024 to drive strong financial results.
  • $165.1MAdjusted net income for 2025 reached $165.1 million compared to $108.5 million in 2024.
  • $11.5MChief Executive Officer Todd C. Davis received total compensation of $11,472,095 for fiscal year 2025.
  • 92.6%Stockholders overwhelmingly approved the 2025 say-on-pay resolution with approximately 92.6% support.
  • 94%Variable or at-risk compensation constituted 94% of total target direct compensation for our CEO.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.